Merck's Q3 2015 earnings call highlighted strong KEYTRUDA performance and continued growth in JANUVIA, bolstering the company's overall financial picture.  Management's tone is upbeat, emphasizing KEYTRUDA's broad clinical potential and JANUVIA's resilience despite competitive pressure.  Positive guidance updates and share buybacks suggest confidence in the future, likely driving positive investor sentiment and short-term stock price gains.
[1]
